OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral ...
The Manila Times

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a ...
The Manila Times

Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic

Under the partnership, Phare Bio will deploy its Generative AI platform to design molecules with antibacterial properties ...

Precision Engineering: ProMed Optimizes the LSR Injection Molding Process for Medical Devices

ProMed, a contract manufacturer specializing in liquid silicone rubber (LSR) and highly regulated combination products, has announced new process refinements in the LSR injection molding process ...

Azafaros Further Strengthens Its Board of Directors With Appointment of Biotech Entrepreneur Dr. Thierry Abribat

Dr. Abribat has a proven track record of developing innovative treatments for rare diseases, achieving three successful biotech/company exits He is a seasoned scientific and operational leader ...
Kauppalehti

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health ...